Saprirearine is primarily used in the development of antiviral therapies, particularly targeting RNA viruses. It functions as a nucleoside analog, interfering with viral replication by inhibiting RNA-dependent RNA polymerase. This makes it a key candidate in the treatment of certain viral infections, especially those with limited therapeutic options. Its application extends to preclinical research for emerging viral diseases, where it demonstrates potential in reducing viral load. Additionally, saprirearine is being studied for its ability to cross biological barriers, such as the blood-brain barrier, which may allow for effective targeting of neurotropic viruses. Due to its mechanism of action and metabolic stability, it is also explored in combination therapies to enhance antiviral efficacy and reduce the risk of resistance development.